MedTrace Logo

Impact of Therapeutic Educational Programme on the Alzheimer's Disease Affected Patient's Quality of Life

NCT01796314 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2021-11-01

No results posted yet for this study

Summary

Therapeutic education expands in Alzheimer's Disease management in France. Several studies revealed a positive impact on caregiver's burden and/or quality of life. The purpose of this study, is to determine whether a therapeutic educational programme for both AD patients and primary caregivers, in community dwelling, improves patient's quality of life.

Conditions

  • Alzheimer Disease

Interventions

BEHAVIORAL

Therapeutic Educational Program

The intervention is a therapeutic educational programme as recommended in the care of Alzheimer's disease. It includes two consultations for the dyad AD patient/caregiver and four group sessions, one a week, for caregivers only. The intervention length is 2 months. These collective sessions focus on : 1. Knowledge of the disease 2. Pharmacological and non pharmacological treatments. Behavioural and psychological symptoms of dementia 3. Crisis situations. Prevention of caregiver's exhaustion 4. Assistive devices and care pathways. Monitoring will consist of a two consultations to 6 and 12 months including assessment of secondary outcome measures.

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Hélène VILLARS, MD

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01796314 on ClinicalTrials.gov